AFP and neoplasm: It seems that lenvatinib is effective against more aggressive tumors (AFP > 200 ng/mL and tumor size > 5 cm), and post-sorafenib treatment is effective with a lower tumor burden (AFP ≤ 200 ng/mL and tumor size ≤ 5 cm).